TG Therapeutics
$24.54
24H
Market Cap
Volume
Supply
Price Chart
About TG Therapeutics - TGTX
TG Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. They aim to create and market therapies that can enhance the quality of life and provide new treatment options for patients with these conditions.
What are TG Therapeutics's core values and mission statement?
TG Therapeutics, Inc. is focused on developing and delivering medicines for patients with B-cell malignancies and autoimmune diseases, striving to improve the quality of life for patients and their families through their commitment to innovative therapies. Their mission is centered on acquiring, developing, and commercializing novel treatments for these conditions with the goal to provide new options for patient care.
Who founded TG Therapeutics and when?
TG Therapeutics, Inc. was founded by Michael S. Weiss in 1993.
Who leads TG Therapeutics?
As of the last update, Michael S. Weiss is the Executive Chairman, President, and CEO of TG Therapeutics, Inc.
Where is TG Therapeutics located, and what is its base country?
TG Therapeutics, Inc. is headquartered in New York City, and its base country is the United States.
On which exchanges is TG Therapeutics traded?
TG Therapeutics, Inc. is traded on the Nasdaq Stock Market under the ticker symbol TGTX.
Historical data
TG Therapeutics (TGTX) Price Live Data
The live price of TG Therapeutics (TGTX) is $24.54, with a trading volume of 4,872,949 in the last 24 hours. Wrapstocks updates the TGTX price in real-time. TG Therapeutics is down -2.95% in the last 24 hours. The company has a live market cap of $3,798,582,528.00 and a supply of 154,823,009 TGTX stocks.
TG Therapeutics (TGTX) is traded on NASDAQ Stock Exchange, and currently, the market is closed; trading will be resumed in 10 hours and 33 minutes.
